<DOC>
	<DOCNO>NCT02561455</DOCNO>
	<brief_summary>The purpose study provide access continue treatment subject participate Astellas sponsor ASP2215 trial Investigator feel subject may benefit continued treatment .</brief_summary>
	<brief_title>Rollover Study Subjects Who Have Participated Astellas Sponsored ASP2215 Trial</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Subject must currently participate Astellas sponsor , single agent ASP2215 trial , receive ASP2215 enroll rollover study without interruption study drug , 2 week interruption study drug . Subject must derive benefit continued treatment determine Investigator . Female subject must either : Be nonchildbearing potential : postmenopausal ( define least 1 year without menses ) prior Screening , document surgically sterile ( least 1 month prior Screening ) Or , childbearing potential , Agree try become pregnant study 45 day final study drug administration ; And negative urine pregnancy test Day 1 ; And , heterosexually active , agree consistently use two form highly effective birth control ( least one must barrier method ) start Screening throughout study period 45 day final study drug administration . Female subject must agree breastfeed start Screening throughout study period , 45 day final study drug administration . Female subject must donate ovum start Screening throughout study period , 45 day final study drug administration . Male subject female spouse/partners childbearing potential must use highly effective contraception consist two form birth control ( least one must barrier method ) start Screening continue throughout study period , 105 day final study drug administration . Male subject must donate sperm start Screening throughout study period , 105 day final study drug administration . Subject agree participate another interventional study treatment . Subject require treatment concomitant drug strong inducer cytochrome P450 ( CYP ) 3A4 strong inhibitor inducer Pglycoprotein ( Pgp ) substrates multidrug toxin extrusion protein 1 ( MATE1 ) exception drug consider absolutely essential care subject . Subject require treatment concomitant drug target serotonin 5hydroxytryptamine receptor 1 ( 5HT1R ) 5hydroxytryptamine receptor 2B ( 5HT2BR ) sigma nonspecific receptor exception drug consider absolutely essential care subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>ASP2215</keyword>
</DOC>